The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment

Hajjar, Ihab; Schumpert, Jeannie; Hirth, Victor; Wieland, Darryl; Eleazer, G. Paul

doi:10.1093/gerona/57.7.m414

Cited by 168 publications

(102 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HDL in this cohort of middle age women was not associated with memory [34]. Others have noted that the use of HMG-CoA-reductase inhibitors (statins) is associated with a lower prevalence of dementia [35]. However, as the authors pointed out, there may be a selection bias influencing the observed relationship, since statins may be less likely to be prescribed to patients with dementia [35].…”

Section: Comorbiditiesmentioning

confidence: 64%

“…Others have noted that the use of HMG-CoA-reductase inhibitors (statins) is associated with a lower prevalence of dementia [35]. However, as the authors pointed out, there may be a selection bias influencing the observed relationship, since statins may be less likely to be prescribed to patients with dementia [35]. Another study examining the impact of plasma lipids on memory performance in healthy elderly individuals found no association between changes in cognition and plasma triglycerides, LDL or treatment with lipid lowering agents [36].…”

Section: Comorbiditiesmentioning

confidence: 99%

See 1 more Smart Citation

Diabetes, sugar-coated but harmful to the brain

Starr

Convit

2007

Current Opinion in Pharmacology

View full text Add to dashboard Cite

Section: Comorbiditiesmentioning

confidence: 64%

Section: Comorbiditiesmentioning

confidence: 99%

Diabetes, sugar-coated but harmful to the brain

Starr

Convit

2007

Current Opinion in Pharmacology

View full text Add to dashboard Cite

“…This may be an effect of the treatment of hypercholesterolemia with statins. Studies have shown that the use of statins can reduce the risk of the onset of dementia, and is correlated with a reduced prevalence of dementia (Haag et al 2009;Hajjar et al 2002). Furthermore, the use of statins has been shown to delay the progression of cognitive impairments (Hajjar et al 2002), and therefore to reduce the risk of LTC among patients with dementia.…”

Section: Discussionmentioning

confidence: 99%

Health Among the Elderly in Germany. New Evidence on Disease, Disability and Care Need

Doblhammer¹

2014

View full text Add to dashboard Cite

“…Podobno je dokazal tudi Hajjar s sodelavci (76), ki je raziskoval povezavo med uporabo statinov in prevalenco demence ter vpliv statinov na napredovanje kognitivnega upada. Ugotovil je, da je raba statinov povezana z nižjo prevalenco demence in upočasnjuje upad spoznavnih sposobnosti.…”

Section: Vpliv Povišanih Maščobunclassified

Vaskularni kognitivni upad in vaskularna demenca

Štante

Potočnik

Rakuša³

2017

SlovMedJour

View full text Add to dashboard Cite

IzvlečekV razvitem svetu ima 5-10 % prebivalstva nad 65 let demenco, katere pojavnost še vedno narašča. Demence zaradi možganskih žilnih bolezni -vaskularna demenca (VaD) predstavljajo dobro petino vseh vzrokov za demenco. Milejša oblika je vaskularni kognitivni upad (VaKU). Za postavitev diagnoze VaD je pomembno, da sta upad spoznavnih sposobnosti in možgansko-žilna bolezen jasno časovno povezana ter ni popravljivih vzrokov za kognitivni upad. Pri postavitvi diagnoze uporabimo nevropsihološko testiranje in slikovne preiskave.Glavni dejavniki tveganja za VaKU in VaD so starost, ateroskleroza, sladkorna bolezen in arterijska hipertenzija, ki sprožijo kaskado dogodkov v patogenezi kognitivne okvare. Ta je zelo raznolika in poteka z ali brez pridruženih nevroloških simptomov. Klinična slika je odvisna od področja in velikosti možganske spremembe.Pri zdravljenju VaKU in VaD je najbolj pomembna primarna preventiva. Za zdravljenje simptomov VaKU in VaD se uporabljajo enaka zdravila kot za zdravljenje simptomov Alzheimerjeve bolezni. Pomembni sta še rehabilitacija in sekundarna preventiva ponovne možganske kapi. AbstractIn the developed world, five to ten percent of people older than 65 years have dementia. One fifth of dementia etiologies are due to vascular brain lesions (VaD -vascular dementia). A milder form is called vascular cognitive impairment (VCI). The main clinical criteria for VaD are: 1. cognitive decline verified with standardized cognitive test/scale, 2. evidence of the associated vascular brain lesion, 3. excluded reversible causes of cognitive decline.The main risk factors for VaD are age, atherosclerosis, diabetes and hypertension. They play a key role in pathogenesis of the cognitive impairment. Depending on the damaged brain region, different cognitive domains may be affected with or without other neurological signs. These diversities in the clinical picture challenge the correct diagnosis. Unique feature of VaD is its progression, which can be stopped, if patients receive an appropriate treatment.The treatment of VCI and VaD symptoms is similar to that in Alzheimer's disease. More importantly, VCI may be slowed down or even stopped with proper secondary stroke prevention and good rehabilitation. The most efficient is primary stroke prevention with healthy lifestyle and treatment of acquired risk factors.

show abstract

The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment

Abstract: The use of statins is associated with a lower prevalence of dementia and has a positive impact on the progression of cognitive impairment.

Cited by 168 publications

References 29 publications

Diabetes, sugar-coated but harmful to the brain

Diabetes, sugar-coated but harmful to the brain

Health Among the Elderly in Germany. New Evidence on Disease, Disability and Care Need

Vaskularni kognitivni upad in vaskularna demenca

Contact Info

Product

Resources

About